Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
C4 Therapeutics, Inc. CCCC
$3.26
-$0.11 (-3.26%)
На 18:03, 12 мая 2023
+247.55%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
162155859.00000000
-
week52high
13.24
-
week52low
2.85
-
Revenue
31096000
-
P/E TTM
-1
-
Beta
2.11222700
-
EPS
-2.70000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 12:00
Описание компании
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 09 мая 2022 г. |
| Credit Suisse | Underperform | 28 апр 2022 г. | |
| UBS | Buy | Buy | 18 апр 2022 г. |
| BMO Capital | Outperform | Outperform | 11 апр 2022 г. |
| JP Morgan | Overweight | 10 мар 2022 г. | |
| Morgan Stanley | Underweight | 11 окт 2022 г. | |
| Wells Fargo | Equal-Weight | Equal-Weight | 08 ноя 2022 г. |
| JP Morgan | Neutral | Overweight | 04 ноя 2022 г. |
| Wells Fargo | Equal-Weight | Equal-Weight | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Fisher Stewart | D | 18750 | 3750 | 30 янв 2023 г. |
| Fisher Stewart | D | 76487 | 1301 | 30 янв 2023 г. |
| Fisher Stewart | A | 77788 | 3750 | 30 янв 2023 г. |
| Siegel Jolie | D | 18750 | 3750 | 30 янв 2023 г. |
| Siegel Jolie | D | 5097 | 1301 | 30 янв 2023 г. |
| Siegel Jolie | A | 6398 | 3750 | 30 янв 2023 г. |
| Schick Kelly | D | 18750 | 3750 | 30 янв 2023 г. |
| Schick Kelly | D | 5097 | 1301 | 30 янв 2023 г. |
| Schick Kelly | A | 6398 | 3750 | 30 янв 2023 г. |
| Hirsch Andrew | D | 62500 | 12500 | 30 янв 2023 г. |
Новостная лента
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 07:00
WATERTOWN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the Company will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9th at 10:30 am PST (1:30 pm EST).
C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Lags Revenue Estimates
Zacks Investment Research
03 ноя 2022 г. в 09:48
C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 0% and 30.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022
GlobeNewsWire
26 сент 2022 г. в 07:00
WATERTOWN, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that C4T management will participate in a fireside chat at the virtual Bank of America Securities Precision Oncology Conference 2022.
C4 Therapeutics: Poor Data Destroyed Preclinical Promise
Seeking Alpha
04 мая 2022 г. в 08:50
CCCC showed a lot of preclinical promise for its protein degrader platform. However, first clinical data presented at AACR has destroyed the stock.
Why C4 Therapeutics Stock Is Plunging Today
Benzinga
08 апр 2022 г. в 15:07
C4 Therapeutics Inc (NASDAQ: CCCC) shares are trading significantly lower Friday afternoon after the company presented data from Cohort A of its ongoing Phase 1/2 clinical trial of CFT7455. Cohort A, the first cohort in the clinical trial, explored CFT7455 as a single agent and enrolled five.